Analysts Set $3.38 Target Price for Biopharmx Corp (BPMX)

Shares of Biopharmx Corp (NASDAQ:BPMX) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus target price of $3.38 for the company and are expecting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Biopharmx Corp an industry rank of 114 out of 265 based on the ratings given to its competitors.

Several research analysts have recently issued reports on BPMX shares. Roth Capital set a $3.00 price objective on Biopharmx Corp and gave the company a “buy” rating in a research note on Saturday, March 25th. HC Wainwright set a $3.00 price objective on Biopharmx Corp and gave the company a “buy” rating in a research note on Monday, March 27th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Biopharmx Corp in a research note on Thursday, May 4th.

Shares of Biopharmx Corp (BPMX) remained flat at $0.47 during midday trading on Tuesday. The stock had a trading volume of 258,306 shares. The firm’s market cap is $34.84 million. Biopharmx Corp has a 12 month low of $0.19 and a 12 month high of $1.22. The stock’s 50 day moving average is $0.51 and its 200-day moving average is $0.51.

Biopharmx Corp (NASDAQ:BPMX) last posted its quarterly earnings data on Tuesday, June 13th. The company reported ($0.07) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. Biopharmx Corp had a negative net margin of 28,405.26% and a negative return on equity of 1,847.04%. On average, equities research analysts anticipate that Biopharmx Corp will post ($0.31) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by [[site]] and is owned by of [[site]]. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at [[permalink]].

In other news, major shareholder Vivo Capital Fund Viii, L.P. acquired 1,282,052 shares of the stock in a transaction dated Friday, April 28th. The stock was bought at an average price of $0.78 per share, with a total value of $1,000,000.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com